全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Yislenz Narváez-Martínez , Napoleón de la Ossa , Raquel López-Martos ...
来源:[J].Neurocirugía(IF 0.343), 2017, Vol.28 (4), pp.190-196Elsevier
摘要:... Several entities have to be considered, including melanin-containing tumours (melanotic ependymoma and melanotic schwannoma) and melanocyte-containing tumours (melanocytoma, primary melanoma and melanoma metastases). The case is presented of a 47 year-old male with a pigmente...
作者:Priscila Daniele Ramos Cirilo , Luciana Nogueira de Sousa Andrade , Bruna Renata Silva Corrêa ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:Melanoma is the most lethal type of skin cancer. Since chemoresistance is a significant barrier, identification of regulators affecting chemosensitivity is necessary in order to create new forms of intervention. Prohibitin 1 (PHB1) can act as anti-apoptotic or tumor suppressor mo...
作者:Liang Song , Ewan M. McNeil , Ann-Marie Ritchie ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:The global incidence of melanoma has been increasing faster than any other form of cancer. New therapies offer exciting prospects for improved survival, but the development of resistance is a major problem and there remains a need for additional effective melanoma therapy. Platin...
作者:Messaouda Merzoug-Larabi , Caroline Spasojevic , Marianne Eymard ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:Melanoma is a highly metastatic type of cancer that is resistant to all standard anticancer therapies and thus has a poor prognosis. Therefore, metastatic melanoma represents a significant clinical problem and requires novel and effective targeted therapies. The protein kinase C ...
作者:Jérôme Fernandes , Bruno Bregman , Patrick Combemale ...
来源:[J].BMC Health Services Research(IF 1.773), 2017, Vol.17 (1)Springer
摘要:Management of metastatic melanoma is changing rapidly following the introduction of innovative effective therapies, with consequences for the allocation of healthcare resources. The objective of this study was to assess hospitalisation costs of metastatic melanoma in France from ...
作者:J. De Smedt , S. Van Kelst , V. Boecxstaens ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:Previous studies have investigated the protective effect of vitamin D serum levels, at diagnosis and during the follow-up period after treatment, on melanoma outcome. In the present study we assess whether vitamin D supplementation, in the follow-up period after diagnosis and sur...
作者:Łukasz Kuźbicki , Dariusz Lange , Agata Stanek-Widera ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:... The expression pattern of JARID1B in human melanoma seems to be different from observed in other cancers. Moreover, up to now no data on the impact of JARID1B expression in cutaneous melanoma on the patients’ prognosis have been reported.
作者:Xiaojing Li , Zhifeng Li , Xianping Li ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:Malignant melanoma (MM) is one of the high degree of malignancy and early prone to blood and lymph node metastasis. There is not cured for MM. Tan II A has been reported to reduce cancer cell proliferation. But the mechanism by which Tan II A inhibited melanoma growth are not wel...
作者:Shota Kuwabara , Yuma Ebihara , Yoshitsugu Nakanishi ...
来源:[J].BMC Surgery(IF 1.973), 2017, Vol.17 (1)Springer
摘要:Primary malignant melanoma of the esophagus (PMME) is a rare disease with a poor prognosis. There are few reports of early-stage cases in which tumor invasion reached the lamina propria or muscularis mucosae, as in the present case. A standard treatment for early-stage PMME has n...
作者:Bernies van der Hiel , John B.A.G. Haanen , Marcel P.M. Stokkel ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:In patients with BRAFV600 mutated unresectable stage IIIc or metastatic melanoma, molecular targeted therapy with combined BRAF/MEK-inhibitor vemurafenib plus cobimetinib has shown a significantly improved progression-free survival and overall survival compared to treatment with ...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×